Albiglutide (GLP-1 RA) was proved superior to placebo in reduction of primary composite endpoint (CV death,nonfatal MI, and nonfatal stroke; expanded composite outcome (CV death, nonfatal MI, nonfatal stroke, and urgent coronary revascularization for UA; and fatal or nonfatal MI, but not for overall mortality, CV death or stroke (fatal or nonfatal). Significantly reduced HbA1c. The gene discussed is GCG; the disease is stroke disorder.